Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bufei Granules is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Tianjin Zhongxin Pharmaceutical Group's Daren Tang Pharmaceutical Factory. It is primarily indicated for the treatment of chronic obstructive pulmonary disease (COPD) and other chronic respiratory conditions characterized by lung and kidney qi deficiency. The formulation is a complex mixture of herbal extracts, typically including *Astragalus membranaceus* (Huangqi), *Rehmannia glutinosa* (Shudihuang), *Codonopsis pilosula* (Dangshen), *Schisandra chinensis* (Wuweizi), *Morus alba* (Sangbaipi), and *Aster tataricus* (Ziwan). Pharmacologically, Bufei Granules exhibits anti-inflammatory, anti-oxidative, and immunomodulatory properties, helping to reduce airway inflammation, improve pulmonary ventilation, and enhance the quality of life for patients in the stable phase of COPD. It is administered orally as granules dissolved in warm water.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bufei Granules.